EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Unraveling the role of CARM1 in Alzheimer’s disease: molecular mechanisms and therapeutic potential

Sunit Kumar Gupta, Khadga Raj Aran

Inflammopharmacology · 28.10.2026

DOI: 10.1007/s10787-026-02435-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 28.10.2026. Verfasst von Sunit Kumar Gupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurological condition that has manifestations of cognitive decline, accumulation of neurofibrillary tau pathology, amyloid-β (Aβ), synaptic dysfunction, neuroinflammation, oxidative stress, and cerebrovascular abnormalities. Evidence is growing that epigenetic dysfunction is involved in the development of AD. The coactivator-associated arginine methyltransferase 1 (CARM1), also known as protein arginine methyltransferase 4 (PRMT4), is an epigenetic enzyme that functions in transcriptional control, chromatin remodeling, maintenance of cellular homeostasis, and neuronal functions. CARM1-mediated histone H3 arginine 17 methylation (H3R17me2a) and NF-κB-dependent transcription provide a link to inflammatory gene regulation; however, a direct role for CARM1 in AD-associated neuroinflammation remains unconfirmed. Findings from cultured hippocampal neurons implicate CARM1 in dendritic maturation and synaptic organization, although these effects have not established therapeutic benefits in AD models. Evidence from female 3xTg-AD mice indicates that pharmacological CARM1 inhibition can improve selected cerebrovascular parameters, including nitric oxide synthase coupling and cerebral blood flow. CARM1 phosphorylation may also influence its enzymatic activity and localization, but its involvement in AD-related neuronal pathology remains hypothetical. The aim of this study is to put together in a comprehensive manner the role of CARM1 in the molecular and cellular mechanisms involved in AD pathology and its potential as a therapeutic target. Future studies should focus on brain penetrants and selective CARM1 modulators, cell-specific functions, long-term safety, target engagement, and clinical translation. In conclusion, CARM1 may be a potential AD therapeutic target that is still in the preclinical phase.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseCARM1Cerebrovascular dysfunctionEpigenetic regulationNeuroinflammationPRMT4Synaptic plasticity

Autor:innen und Institutionen

  • Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India.
  • Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, 142001, India. bishalarann@gmail.com.
  • Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India. bishalarann@gmail.com.

Zitieren

APA

Gupta, S. K., & Aran, K. R. (2026). Unraveling the role of CARM1 in Alzheimer’s disease: molecular mechanisms and therapeutic potential. Inflammopharmacology. https://doi.org/10.1007/s10787-026-02435-8

Vancouver

Gupta SK, Aran KR. Unraveling the role of CARM1 in Alzheimer’s disease: molecular mechanisms and therapeutic potential. Inflammopharmacology. 2026. doi:10.1007/s10787-026-02435-8

BibTeX
@article{Gupta2026,
  author = {Gupta, Sunit Kumar and Aran, Khadga Raj},
  title = {Unraveling the role of CARM1 in Alzheimer’s disease: molecular mechanisms and therapeutic potential},
  journal = {Inflammopharmacology},
  year = {2026},
  doi = {10.1007/s10787-026-02435-8}
}
Kostenlos starten →